Could ketamine speed up depression relief in hospitalized patients?
NCT ID NCT06508710
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 3 trial tests whether adding intravenous ketamine to the antidepressant venlafaxine can relieve severe depression faster than venlafaxine alone. Sixty hospitalized adults with major depression will receive either ketamine or placebo infusions over one week. The goal is to see if ketamine can improve symptoms within days, potentially shortening hospital stays and reducing suffering.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- ketamine
- What this could lead to
- If it works, this could provide a faster way to relieve severe depression in hospitalized patients, potentially reducing suffering and hospital stays.
- What could go wrong
- This is a small, early-phase trial with only 60 participants. Ketamine may not work better than placebo, and side effects like dissociation or blood pressure changes are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2024
- Expected to finish
-
Apr 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Current MDE in the context of unipolar major depressive disorder (DSM-5 criteria), hospitalized (open care) for this episode, with a minimum HDRS score of 24 and in the context of an indication for the introduction of venlafaxine treatment. * Patient aged between 18 and 65. * Signed free and informed consent * Membership of a social security scheme * For women of childbearing age, effective contraception throughout study participation.\* (\*Combined hormonal contraception (containing estrogen and progestin) associated with ovulation inhibition: (oral, intravaginal, transdermal), Progestin-only hormonal contraception associated with ovulation inhibition: (oral, injectable, implantable), Intrauterine device (IUD), Hormonal intrauterine system (IUS), Bilateral tubal occlusion, Vasectomized partner, Sexual abstinence.) Exclusion Criteria: * Criteria relating to associated pathologies entailing particular risks: pharmaco-resistant CDE (failure of at least two properly conducted treatments with two different antidepressant treatment classes), CDE with psychotic features, psychotic disorder, bipolar disorder, current (\<1 month) substance use disorder (excluding tobacco). * Liver impairment (AST and/or ALT \> 3 ULN, PAL and/or GGT and/or bilirubin \> 2 ULN). * Severe renal insufficiency (GFR \<30ml/min with Cockcroft's formula). * Bradycardia less than 55 beats per minute. * Contraindication to ketamine : Hypersensitivity to active substance or excipients, comatose state, central nervous system (CNS) depression, Parkinson's disease, Lewy body dementia, progressive supranuclear palsy, known prolongation of the QTc interval (\>450ms for men and \>470ms for women) or congenital long QT syndrome, recent acute myocardial infarction, uncompensated heart failure, history of ventricular arrhythmias or torsades de pointes, uncorrected hypokalemia (K+ \< 3. 5 mmol/l), epilepsy, uncontrolled hypertension, porphyria, history of stroke (CVA), intracranial hypertension. * Contraindication to venlafaxine (hypersensitivity to venlafaxine or excipients, are hereditary conditions of fructose intolerance, glucose-galactose malabsorption syndrome, or sucrase-isomaltase deficiency, unstable hypertension, no indication for venlafaxine treatment in clinician's opinion due to ineffectiveness or tolerability of previous venlafaxine treatment). * Current or previous treatment with venlafaxine or ketamine in the month prior to study inclusion. * Need to maintain another antidepressant, MAOI, Millepertuis or benzodiazepines (cyamemazine is permitted). Or potential drug interactions in case of recent cessation of these treatments (based on the Summary of Product Characteristics (SmPC) of the respective medication(s) and their half-life). * Any other unspecified reason (clinically significant illness or anomaly) which, in the opinion of the investigator or the sponsor, could compromise the safety of the participant. * Pregnant or breast-feeding patients (women of childbearing potential must have a negative urine or blood test for human chorionic gonadotropin prior to trial entry). Planned pregnancy within three months of enrolment * Adult under guardianship, curatorship or safeguard of justice * Participating in other interventional research involving the human body or within the exclusion period following previous research involving the human body, if applicable. * Social insurance Additional criteria for inclusion in the ancillary study : \- Contraindications to \[11C\]UCB-J PET-MRI 1. Absolute contraindications: Pacemaker or neurosensorial stimulator or implantable defibrillator; clip on a brain aneurysm or vascular malformation; intraocular or intracerebral ferromagnetic foreign body; prostheses or objects or mobile ferromagnetic metal fragments; cochlear implants; peripheral stimulator; neurosurgical ventriculoperitoneal shunt valves; automated injection device such as insulin pump, glucose sensor; permanent eyelid or lip makeup; non-removable piercing; claustrophobia. 2. Relative contraindications: Dental prostheses and orthodontic material; certain intrauterine devices; certain tattoos; certain transdermal patch implants; certain metal implants far from the examined area. (The investigator physician and/or radiology operator will always conduct a precise questionnaire before the examination to ensure perfect safety and absence of MRI danger)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Major depressive episode are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Bicetre Hospital - CRC
NOT_YET_RECRUITINGLe Kremlin-Bicêtre, 94250, France
-
CEA/SHFJ
ACTIVE_NOT_RECRUITINGOrsay, 94401, France
-
EPS Barthélémy Durand
NOT_YET_RECRUITINGÉtampes, 91152, France
-
Psychiatry unit
RECRUITINGLe Kremlin-Bicêtre, France, 94270, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sound waves vs. depression: can focused ultrasound lift mood?
- Can brain activity reveal why some people with depression lose motivation and pleasure?
- Can a targeted magnetic pulse rewire the depressed brain?
- Can a simpler brain stimulation match the gold standard for depression?
- Magnetic brain pulses could offer Drug-Free hope for teen depression
- Decoding depression: sleep rhythms as biomarkers?